Paloma Partners’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Paloma Partners’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-191	Closed	-$7K	–	2010
2018 Q4	$7K	Buy	+191	New	+$13.8K	﹤0.01%	1206
2015 Q3	–	Sell	-99	Closed	-$99K	–	1997
2015 Q2	$99K	Buy	+99	New	+$107K	﹤0.01%	1682

Other funds holding NBSE

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MIG

Mariner Investment Group Harrison, New York $346M AUM 25.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SSB

Sandy Spring Bank Olney, Maryland $2.38B AUM 8.14% 1-Year Est. Return

WAM

Wealthspire Advisors (Maryland) Potomac, Maryland $2.84B AUM 10.91% 1-Year Est. Return

Paloma Partners's NBSE Position: Q1 2019 in Review

Paloma Partners sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2019, closing a stake of 191 shares — an estimated $7K sold.

Paloma Partners first reported a position in NBSE in Q2 2015 and held it in 2 quarters. The position peaked at $99K in Q2 2015. 15 funds tracked by Wall St. Rank hold NBSE as of Q1 2019.

Paloma Partners reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Paloma Partners sold 191 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $7K.
Paloma Partners first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2015 and held it in 2 quarters.
Paloma Partners's NeuBase Therapeutics, Inc. Common Stock position peaked at $99K in Q2 2015.
15 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Paloma Partners's 13F filing for Q1 2019, filed 15 May 2019.